We claim

1. A composition, comprising particles comprising at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m^2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

2. The composition of claim 1, wherein the particles have a SSA of at least 15 m^2/g.

3. The composition of claim 1, wherein the particles have a SSA of at least 18 m^2/g.

4. The composition of any one of claims 1-3, wherein the particles have a SSA of between 10 m^2/g and 50 m^2/g, between 15 m^2/g and 50 m^2/g, or between 18 m^2/g and 50 m^2/g.

5. The composition of any one of claims 1-4, wherein the particles have a mean particle size by volume distribution of between about 1 μm and about 8 μm.

6. The composition of any one of claims 1-5, wherein the particles comprise at least 96%, 97%, 98%, 99%, or 100% of lapatinib, or a pharmaceutically acceptable salt thereof.

7. The composition of any one of claims 1-6, wherein the particles are uncoated and exclude polymer, protein, polyethoxylated castor oil and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.

8. The composition of any one of claims 1-7, wherein the composition comprises a suspension further comprising a pharmaceutically acceptable liquid carrier.

9. The composition of any one of claims 1-8, further comprising one or more components selected from the group consisting of polysorbate, methylcellulose, polyvinylpyrrolidone, mannitol, and hydroxypropyl methylcellulose.

10. The composition of any one of claims 1-9, wherein

(a) the particles have a mean bulk density between about 0.005 g/cm^3 and about 0.100 g/cm^3, between about 0.010 g/cm^3 and about 0.075 g/cm^3, between about 0.010 g/cm^3

and about 0.050 g/cm^3, or between about between about 0.015 g/cm^3 and about 0.040 g/cm^3, tapped or not tapped; and/or

(b) the particles have a mean bulk density less than about 0.100 g/cm^3, 0.090 g/cm^3, 0.080 g/cm^3, 0.070 g/cm^3, 0.060 g/cm^3, , 0.050 g/cm^3, 0.040 g/cm^3, or 0.030 g/cm^3, tapped or not tapped.

11. The composition of any one of claims 1-10, wherein the pharmaceutically acceptable salt of lapatinib comprises lapatinib ditosylate monohydrate.

12. A method for treating a tumor, comprising administering to a subject with a tumor an amount effective to treat the tumor of the composition of any one of claims 1-11.

13. The method of 12, wherein the tumor is a breast tumor, pancreatic carcinoma, prostate carcinoma, bladder carcinoma, lung carcinoma, ovarian carcinoma, gastrointestinal tumor, or renal cell tumor.

14. The method of claim 13, wherein the tumor is a breast tumor, and wherein the breast tumor is an advanced or metastatic breast tumor that overexpresses human epidermal growth factor 2 (HER2), or a hormone receptor positive metastatic breast tumor that overexpresses the HER2 receptor.

15. The method of claim 13 or 14, wherein the method further comprises administering capecitabine and/or letrozole to the subject.

16. The method of any one of claims 12-15, wherein the subject is a human subject, including but not limited to a female human subject, including but not limited to a post-menopausal female human subject.

17. The method of any one of claims 12-16, wherein the composition is administered by intra-tumoral injection, peri-tumoral injection, intra-peritoneal injection, or is administered into a mammary fat pad.

18. A method for making lapatinib particles, comprising:

(a) introducing (i) a solution comprising at least one solvent selected from the group consisting of acetone and DCM, or combinations thereof, and at least one solute comprising lapatinib or a pharmaceutically acceptable salt thereof into a nozzle inlet, and (ii) a compressed fluid into an inlet of a vessel defining a pressurizable chamber;

(b) passing the solution out of a nozzle orifice and into the pressurizable chamber to produce an output stream of atomized droplets, wherein the nozzle orifice is located between 2 mm and 20 mm from a sonic energy source located within the output stream, wherein the sonic energy source produces sonic energy with an amplitude between 10% and 100% during the passing, and wherein the nozzle orifice has a diameter of between 20 μm and 125 μm;

(c) contacting the atomized droplets with the compressed fluid, to cause depletion of the solvent from the atomized droplets, to produce compound particles comprising at least 95% lapatinib or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m^2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm,

wherein steps (a), (b), and (c) are carried out under supercritical temperature and pressure for the compressed fluid.

19. The method of claim 18, further comprising:

(d) contacting the compound particles produced in step (c) with an anti-solvent to cause further depletion of the solvent from the compound particles, wherein step (d) is carried out under supercritical temperature and pressure for the anti-solvent.

20. The method of any one of claims 18-19, wherein a flow rate of the solution through the nozzle has a range from about 0.5 mL/min to about 30 mL/min.

21. The method of any one of claims 18-20, wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.

22. The method of any one of claims 18-21, wherein the sonic energy source has a frequency between about 18 kHz and about 22 kHz, or about 20 kHz.

23. The method of any one of claims 18-22, further comprising:

(e) receiving the plurality of particles through the outlet of the pressurizable chamber; and

(f) collecting the plurality of particles in a collection device.

24. The method of any one of claims 18-23, wherein the compressed fluid is super critical carbon dioxide.

25. The method of any one of claims 19-24, wherein the anti-solvent is super critical carbon dioxide.

26. The method of any one of claims 18-25, wherein the method is carried out between 31.1°C to about 60°C, and at between about 1071 psi and about 1800 psi.

27. The method of any one of claims 18-26, wherein the particles have a SSA of at least 15 m^2/g or at least 18 m^2/g.

28. Compound particles prepared by the method of any one of claims 18-27.